JP2020516276A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516276A5 JP2020516276A5 JP2019555484A JP2019555484A JP2020516276A5 JP 2020516276 A5 JP2020516276 A5 JP 2020516276A5 JP 2019555484 A JP2019555484 A JP 2019555484A JP 2019555484 A JP2019555484 A JP 2019555484A JP 2020516276 A5 JP2020516276 A5 JP 2020516276A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- seq
- cell according
- sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024014208A JP2024062986A (ja) | 2017-04-14 | 2024-02-01 | 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762485670P | 2017-04-14 | 2017-04-14 | |
| US62/485,670 | 2017-04-14 | ||
| US201862629593P | 2018-02-12 | 2018-02-12 | |
| US62/629,593 | 2018-02-12 | ||
| PCT/US2018/027783 WO2018191748A1 (en) | 2017-04-14 | 2018-04-16 | Chimeric antigen receptor t cells targeting the tumor microenvironment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024014208A Division JP2024062986A (ja) | 2017-04-14 | 2024-02-01 | 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020516276A JP2020516276A (ja) | 2020-06-11 |
| JP2020516276A5 true JP2020516276A5 (enExample) | 2023-10-26 |
| JP7505885B2 JP7505885B2 (ja) | 2024-06-25 |
Family
ID=63793633
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019555484A Active JP7505885B2 (ja) | 2017-04-14 | 2018-04-16 | 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞 |
| JP2024014208A Pending JP2024062986A (ja) | 2017-04-14 | 2024-02-01 | 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024014208A Pending JP2024062986A (ja) | 2017-04-14 | 2024-02-01 | 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12378297B2 (enExample) |
| EP (1) | EP3609914B1 (enExample) |
| JP (2) | JP7505885B2 (enExample) |
| CN (1) | CN110520524A (enExample) |
| AU (3) | AU2018251206A1 (enExample) |
| CA (1) | CA3059444A1 (enExample) |
| WO (1) | WO2018191748A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3568466A4 (en) | 2017-01-10 | 2020-07-15 | The General Hospital Corporation | TARGETED T CELLS WITH CYTOTOXICITY TO IMMUNOSUPPRESSIVE CELLS |
| US12378297B2 (en) | 2017-04-14 | 2025-08-05 | The General Hospital Corporation | Chimeric antigen receptor T cells targeting the tumor microenvironment |
| CN109970864A (zh) * | 2017-12-28 | 2019-07-05 | 上海细胞治疗研究院 | 一种双向激活共刺激分子受体及其用途 |
| WO2019157533A1 (en) * | 2018-02-12 | 2019-08-15 | The General Hospital Corporation | Chimeric antigen receptors targeting the tumor microenvironment |
| US20220177524A1 (en) * | 2018-07-26 | 2022-06-09 | Nanjing Legend Biotech Co., Ltd. | Nef-containing t cells and methods of producing thereof |
| US20220170097A1 (en) | 2018-10-29 | 2022-06-02 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
| WO2020191486A1 (en) | 2019-03-27 | 2020-10-01 | National Research Council Of Canada | Antigen-binding agents that specifically bind epidermal growth factor receptor variant iii |
| TW202110873A (zh) | 2019-04-30 | 2021-03-16 | 美商聖堤生物科技股份有限公司 | 嵌合受體及其使用方法 |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| EP3747904A1 (en) * | 2019-06-03 | 2020-12-09 | Universität Regensburg | Cd25-specific chimeric antigen receptors and their uses |
| MX2022001711A (es) * | 2019-08-09 | 2022-05-10 | A2 Biotherapeutics Inc | Receptores en la superficie celular que responden a la perdida de heterocigosidad. |
| EP4063387A4 (en) * | 2019-11-22 | 2023-08-02 | Nantong Yichen Biopharma. Co. Ltd. | PSMA ANTIBODIES AND ITS USE |
| CN115052887B (zh) | 2019-12-11 | 2026-03-31 | A2生物治疗公司 | 基于lilrb1的嵌合抗原受体 |
| CN111235113A (zh) * | 2020-01-21 | 2020-06-05 | 南京北恒生物科技有限公司 | 包含嵌合抗原受体的免疫细胞及其用途 |
| GB202008688D0 (en) * | 2020-06-09 | 2020-07-22 | Cancer Research Tech Ltd | Chimeric antigen receptor cell |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| CA3188867A1 (en) | 2020-08-20 | 2022-02-24 | Xueyin Wang | Compositions and methods for treating ceacam positive cancers |
| IL300500A (en) | 2020-08-20 | 2023-04-01 | A2 Biotherapeutics Inc | Preparations and methods for the treatment of mesothelin positive cancer |
| JP2023550148A (ja) * | 2020-11-20 | 2023-11-30 | シンシア・イノベーション・インコーポレイテッド | がん免疫治療に用いられる武装二重ｃａｒ－ｔ組成物及び方法 |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| CN115491358B (zh) * | 2021-06-17 | 2024-09-06 | 复星凯特生物科技有限公司 | 一种靶向b7-h3和folr1双打靶点car t的制备及应用 |
| WO2023274386A1 (zh) * | 2021-07-01 | 2023-01-05 | 宁波茂行生物医药科技有限公司 | 靶向egfr的通用型car-t细胞及其制备方法 |
| TWI823402B (zh) * | 2021-07-21 | 2023-11-21 | 長聖國際生技股份有限公司 | 多特異性單域抗體嵌合抗原受體及t細胞銜接體、核酸、其表達細胞、其用途以及治療癌症之醫藥組合物 |
| WO2023077068A1 (en) * | 2021-10-28 | 2023-05-04 | Skunkworx Bio, Inc. | Novel binding agents related to glycoprotein-a |
| WO2024192289A2 (en) * | 2023-03-14 | 2024-09-19 | The Wistar Institute Of Anatomy And Biology | Tri-specific t-cell engagers and methods of use in cancer therapeutics |
| WO2024196794A2 (en) * | 2023-03-17 | 2024-09-26 | The Children's Hospital Of Philadelphia | Compositions and methods for interneuron mediated delivery of cytotoxic agents to the brain |
| CN119708251A (zh) * | 2023-09-27 | 2025-03-28 | 北京大学 | 一种利用cd27逆转t和car-t细胞pd1信号的工程化细胞方法 |
| WO2025076471A2 (en) * | 2023-10-04 | 2025-04-10 | Ohio State Innovation Foundation | Modulating the tumor immune microenvironment via targeting regulatory t cells (tregs) with chimeric antigen receptor (car) t cell therapy |
| WO2025092689A1 (zh) * | 2023-10-30 | 2025-05-08 | 苏州沙砾生物科技有限公司 | 一种表达多特异性抗原结合蛋白的细胞及其应用 |
| WO2025140683A1 (zh) * | 2023-12-29 | 2025-07-03 | 北京鼎成肽源生物技术有限公司 | 表达趋化因子10和白介素15的工程化免疫细胞 |
| KR20260016890A (ko) * | 2024-07-24 | 2026-02-04 | 서울대학교산학협력단 | 안전하며 효과적인 유전자세포치료 시스템 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| US7112324B1 (en) | 1998-04-21 | 2006-09-26 | Micromet Ag | CD 19×CD3 specific polypeptides and uses thereof |
| PT1478648E (pt) | 2002-02-01 | 2014-07-15 | Ariad Pharma Inc | Compostos contendo fósforo e suas utilizações |
| US20050136035A1 (en) * | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
| US10155038B2 (en) | 2007-02-02 | 2018-12-18 | Yale University | Cells prepared by transient transfection and methods of use thereof |
| EP2331566B1 (en) | 2008-08-26 | 2015-10-07 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| US9349368B1 (en) * | 2010-08-05 | 2016-05-24 | Google Inc. | Generating an audio notification based on detection of a triggering event |
| CA2832540C (en) | 2011-04-08 | 2020-09-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
| US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| JP2015524255A (ja) | 2012-07-13 | 2015-08-24 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 二重特異性抗体を共導入することによってｃａｒｔ細胞の活性を強化する方法 |
| JP6647868B2 (ja) | 2013-02-20 | 2020-02-14 | ノバルティス アーゲー | ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置 |
| CN113684185A (zh) * | 2013-02-26 | 2021-11-23 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| WO2014138306A1 (en) * | 2013-03-05 | 2014-09-12 | Baylor College Of Medicine | Engager cells for immunotherapy |
| CN105283201B (zh) | 2013-03-14 | 2019-08-02 | 斯克利普斯研究所 | 靶向剂抗体偶联物及其用途 |
| WO2014145252A2 (en) * | 2013-03-15 | 2014-09-18 | Milone Michael C | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| ES2860952T3 (es) | 2013-08-01 | 2021-10-05 | Univ Catholique Louvain | Proteína anti-garp y usos de la misma |
| CA2939711C (en) | 2014-02-21 | 2020-09-29 | Cellectis | Method for in situ inhibition of regulatory t cells |
| WO2016016341A1 (en) * | 2014-07-29 | 2016-02-04 | Cellectis | EGFRvIII SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY |
| BR112017005631A2 (pt) | 2014-09-19 | 2018-06-26 | City Of Hope | células t com receptor de antígeno coestimulador quimérico direcionadas à il13ra2 |
| CA2964958A1 (en) * | 2014-10-31 | 2016-05-06 | The Trustees Of The University Of Pennsylvania | Methods and compositions for modified t cells |
| PL3560953T3 (pl) | 2014-12-24 | 2024-05-13 | Autolus Limited | Komórka |
| EP3256492A4 (en) | 2015-02-09 | 2018-07-11 | University of Florida Research Foundation, Inc. | Bi-specific chimeric antigen receptor and uses thereof |
| US9708412B2 (en) * | 2015-05-21 | 2017-07-18 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| EP3340995A4 (en) | 2015-08-28 | 2019-04-03 | The Trustees Of The University Of Pennsylvania | METHOD AND COMPOSITIONS FOR CELLS FOR EXPRESSING A CHIMERIC INTRA-CELLULAR SIGNAL MOLECULE |
| AU2016323985B2 (en) * | 2015-09-17 | 2022-12-15 | Novartis Ag | CAR T cell therapies with enhanced efficacy |
| CN105796597A (zh) | 2016-03-11 | 2016-07-27 | 江苏三特生物科技有限公司 | 携带pd-l1和ctla-4抗体基因的car-t细胞在肿瘤免疫上的应用 |
| KR20230148844A (ko) | 2016-03-29 | 2023-10-25 | 유니버시티 오브 써던 캘리포니아 | 암을 표적하는 키메라 항원 수용체 |
| EP3436480A4 (en) | 2016-03-30 | 2019-11-27 | Musc Foundation for Research Development | METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION |
| US9567399B1 (en) * | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| CN109562126A (zh) | 2016-06-24 | 2019-04-02 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| US20190307799A1 (en) | 2016-09-23 | 2019-10-10 | The Regents Of The University Of Michigan | Engineered lymphocytes |
| US20190338015A1 (en) | 2016-10-19 | 2019-11-07 | Cellectis | Cell death inducing chimeric antigen receptors |
| US20200095301A1 (en) | 2016-12-14 | 2020-03-26 | The Board Of Trustees Of The Leland Stanford Junior University | Il-13 superkine: immune cell targeting constructs and methods of use thereof |
| EP3568466A4 (en) | 2017-01-10 | 2020-07-15 | The General Hospital Corporation | TARGETED T CELLS WITH CYTOTOXICITY TO IMMUNOSUPPRESSIVE CELLS |
| CN110582509A (zh) | 2017-01-31 | 2019-12-17 | 诺华股份有限公司 | 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症 |
| US12378297B2 (en) | 2017-04-14 | 2025-08-05 | The General Hospital Corporation | Chimeric antigen receptor T cells targeting the tumor microenvironment |
| CN107326014B (zh) | 2017-07-31 | 2019-09-24 | 时力生物科技（北京）有限公司 | 一种双特异性嵌合抗原受体修饰的t淋巴细胞及其制备方法和应用 |
| WO2019079034A1 (en) | 2017-10-17 | 2019-04-25 | The General Hospital Corporation | METHODS AND COMPOSITIONS RELATING TO GENETICALLY MODIFIED REGULATORY T LYMPHOCYTES |
| WO2019157533A1 (en) | 2018-02-12 | 2019-08-15 | The General Hospital Corporation | Chimeric antigen receptors targeting the tumor microenvironment |
| JP2023539871A (ja) | 2020-08-26 | 2023-09-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | グリア芽細胞腫を処置するための方法および組成物 |
| WO2023081808A2 (en) * | 2021-11-04 | 2023-05-11 | The General Hospital Corporation | Anti-mesothelin car t cells secreting teams and methods of use thereof |
| AU2023254840A1 (en) * | 2022-04-15 | 2024-11-07 | The General Hospital Corporation | Cd70 binding car-t cells comprising cd33 binding t-cell engaging antibody molecules |
-
2018
- 2018-04-16 US US16/603,675 patent/US12378297B2/en active Active
- 2018-04-16 AU AU2018251206A patent/AU2018251206A1/en not_active Abandoned
- 2018-04-16 CA CA3059444A patent/CA3059444A1/en active Pending
- 2018-04-16 CN CN201880025361.8A patent/CN110520524A/zh active Pending
- 2018-04-16 WO PCT/US2018/027783 patent/WO2018191748A1/en not_active Ceased
- 2018-04-16 EP EP18784599.5A patent/EP3609914B1/en active Active
- 2018-04-16 JP JP2019555484A patent/JP7505885B2/ja active Active
-
2023
- 2023-09-28 US US18/477,532 patent/US20240075070A1/en active Pending
- 2023-12-07 AU AU2023278069A patent/AU2023278069B2/en active Active
-
2024
- 2024-02-01 JP JP2024014208A patent/JP2024062986A/ja active Pending
-
2025
- 2025-07-08 AU AU2025205213A patent/AU2025205213A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020516276A5 (enExample) | ||
| JP7822340B2 (ja) | キメラ抗原受容体およびその使用 | |
| US11136392B2 (en) | PD-1 immune modulating agents | |
| JP7341185B2 (ja) | 前立腺特異幹細胞抗原に対する抗体およびその使用 | |
| JP2021512635A5 (enExample) | ||
| CN111499753B (zh) | 双功能抗体及其用途 | |
| TW201825511A (zh) | 表現免疫檢查點調節子的溶瘤病毒 | |
| CN110035768A (zh) | 嵌合抗原受体 | |
| JP2015513394A (ja) | 二重特異性キメラ抗原受容体およびその治療的使用 | |
| CN115403671A (zh) | 靶向Claudin18.2的纳米抗体及其用途 | |
| US20230348556A1 (en) | Artificial immunosurveillance chimeric antigen receptor and cells expressing the same | |
| US20250051444A1 (en) | Multi-specific t cell engagers comprising lrrc15 antigen-binding domain | |
| JP2025540340A (ja) | キメラ抗原受容体 | |
| CN114853897B (zh) | 抗cd19/cd22/cd3三特异性抗体及用途 | |
| JP2022514815A (ja) | ＣＤＲ１領域に突然変異したヒト化ＣＤ１９ ｓｃＦｖを有するＣＡＲ－Ｔ細胞 | |
| US20250302877A1 (en) | Anti-activated trop-2 chimeric antigen receptor constructs for use in cancer therapy | |
| JP7619682B2 (ja) | Ｃｄ２２に特異的なヒト化抗体およびそれを用いたキメラ抗原受容体 | |
| EP4294830A2 (en) | Antibody-derived t cell activating technologies | |
| JP2024532486A5 (enExample) | ||
| EP4613779A1 (en) | Cd24 binding protein and use thereof | |
| CN115785269B (zh) | 抗pd-l1的抗体及其应用 | |
| US20260060935A1 (en) | Therapeutic effect enhancer for enhancing effect of car-t therapy | |
| US20260077046A1 (en) | Targeting the pvr axis using car t cell therapy and combinations | |
| JP2023527462A (ja) | Ｃｄ２２に特異的な抗体およびその使用 | |
| HK40074322A (en) | Artificial immunosurveillance chimeric antigen receptor and cells expressing the same |